The Grey Peptide Economy

LONGEVITY LATEST | Deep Dive | Issue 09 Companion | 22 April 2026

LONGEVITY LATEST · DEEP DIVE

The Grey Peptide Economy

How a $80 vial of BPC-157 leaves a Hebei industrial park and arrives in a Crouch End bathroom cabinet — and why the FDA crackdown didn't slow it down.

I wanted to know what was in the vial. That sounds like the simplest possible question — and it turns out to be the one nobody in the supply chain can actually answer.

A friend handed me a 5 mg vial last month. "Research peptide, not for human use," the label said. A printed Certificate of Analysis in the box claimed 99.2% purity. Two weeks of reporting later I could tell him where it had started — a Hebei industrial park — and roughly where it had stopped, in his bathroom cabinet in Crouch End. What I learned about everything in between is why this week's issue graded BPC-157 a D, and why I'd grade the supply chain underneath it lower still.

How the chain actually works

Almost every research-chemical peptide sold in the West originates in a Chinese contract synthesis ecosystem. Established suppliers like GL Biochem (Shanghai) and ChinaPeptides (Hangzhou) serve the legitimate research-reagent market and supply universities and biotechs internationally. A larger parallel tier of smaller facilities — most clustered in Hebei, Shandong, and Jiangsu provinces — supplies the grey trade, often without publishing under their own name. Both tiers produce the same solid-phase peptides at industrial scale: BPC-157, TB-500, GHK-Cu, the GHRH analogs, the works. The same precursor batch can be sold three different ways: to a US biotech buying it as labelled reference material for an assay, to an EU compounding pharmacy as an active pharmaceutical ingredient under documented import, and to a reseller who'll repackage it under their own brand and ship it to consumers as a "research chemical."

The price tells you the chain. A gram of high-purity BPC-157 leaves a Chinese facility for roughly $80–$200 wholesale. By the time it's been re-vialed, lyophilised, labelled, photographed for a Shopify store, and shipped from a UK or Estonian fulfilment address, the consumer pays £60–£120 for five milligrams. The markup is forty to eighty times. Almost none of that markup pays for additional quality control. It pays for marketing, for the chargeback risk on the payment processor, and for the fulfilment churn that comes with operating in a legal grey zone.

The reseller tier is where the variance lives. Some operations are essentially relabelling — they take the supplier's existing CoA, swap the logo, and pass the vial through. Others lyophilise from raw powder in environments that would never pass a GMP audit: kitchen-grade laminar hoods on a good day, a clean-ish bench on a less good one. Almost nobody re-tests the material after handling.

I went into this reporting expecting the grey-market problem to be the vials themselves — counterfeit peptide, wrong molecule, the worst-case contamination scenarios that get repeated on the forums. That's not quite what the evidence pointed to. The molecule is often fine at the point of synthesis. What fails is everything that happens to the molecule in the ten thousand kilometres between the Hebei lab bench and the consumer's kitchen counter — the lyophilisation environment, the cold chain, the re-vialing, the weeks sitting in a courier's warehouse, the exposure to humidity on repackaging. The peptide in your friend's bathroom may have been perfect once. By the time it's in a syringe, that's a different question — and the answer is not on the Certificate of Analysis.

The vial in your friend's bathroom may have been 99% pure when it left Hebei. Whether it's still 99% pure six months and three intermediaries later is a question nobody in the chain has actually answered.

Why the FDA crackdown didn't work

In September 2020 the FDA finalised its ruling on Section 503A bulk drug substances and placed BPC-157 in Category 2 — the "raises significant safety risks" tier — alongside other widely-used research peptides. The formal effect was that compounding pharmacies inside the US could no longer use them in patient preparations. Through 2023 and 2024, FDA Import Alert 66-41 (Detention Without Physical Examination of Unapproved New Drugs) increasingly captured peptide shipments at US ports. Several large US-facing retailers quietly relocated fulfilment offshore or shut down.

Supply barely moved. Three reasons.

First, the Chinese synthesis side is entirely outside FDA jurisdiction. The agency can stop product crossing the US border. It cannot stop product being made.

Second, the "research chemical, not for human consumption" disclaimer is a legal fig leaf that has been challenged repeatedly and remains intact in most Western jurisdictions. Selling a substance for non-human research is legal even when both parties know exactly what's actually happening with it.

Third, the consumer demand side only grew. The peptide subreddits and Telegram groups, the wellness podcasters openly running their own stacks on air, the influencers tracking IGF-1 panels — all of it accelerated through 2024 and 2025. Where US-facing retailers retreated, EU and UK ones expanded into the gap. Most supply now passes through Estonian, Cypriot, and increasingly Hong Kong-based payment processors and ships from Eastern European fulfilment hubs.

The crackdown reduced the visibility of the market. It did not reduce the size of it.

The Certificate of Analysis — what it should say, what it does

A real Certificate of Analysis for a pharmaceutical-grade peptide includes, at minimum: identity confirmation by mass spectrometry, purity assay by HPLC with the chromatogram attached, quantitation against a reference standard, residual solvents, water content, microbial bioburden, and — for any injectable — endotoxin testing by LAL assay. It is signed by a named QA officer, dated, and references a batch number that ties back to a production record you could in principle audit.

The CoA tucked into your friend's vial almost certainly contained: a peptide name, a stated purity percentage between 98% and 99.5%, a batch number with no traceability, and a stamp. No chromatogram. No mass-spec data. No endotoxin or microbial testing. No QA signature. The "lab" performing the analysis is frequently the manufacturer itself.

I lined up CoAs from four different research-chemical resellers side by side during this reporting. The visual templates were almost indistinguishable — same column widths, same signature box, same header spacing, same font. What differed was the logo at the top and the percentage on one line. Every one claimed something between 98% and 99.5%. None included the underlying chromatogram. Two used identical batch-number formats — the kind of coincidence that suggests a shared supplier document being reskinned. The 99.2% on your friend's CoA was almost certainly not produced by a fresh HPLC run on his batch. It's the number that gets written on every batch.

If you're going to use one of these vials anyway — and people will — the minimum bar to demand is: an actual HPLC chromatogram for the specific batch (not a typed percentage), a third-party lab name you can independently verify exists, and an LAL endotoxin number for anything you intend to inject. Almost no consumer-facing reseller will provide all three. The few that do are charging £200+ per vial for the privilege of being legitimate.

What this means for you

This is the architecture sitting underneath the £600-a-month clinic offer in last week's newsletter. The clinic is one tier higher in the chain — it adds a prescriber, a private medical premium, and (in the better cases) a sterile compounding pharmacy that has actually re-tested the material. What it does not add is a clinical trial. It does not add long-term safety data. And it does not change the fact that the peptide molecule in the syringe was probably synthesised in the same Chinese industrial park as the £80 vial in the bathroom cabinet.

If a peptide ever justifies its price, it'll be one that has earned its way through real human RCTs — the way tesamorelin did. Until then, the most honest version of the market is the bathroom cabinet, not the Harley Street consultation room. Both are running unproven interventions on real human bodies. One just charges you eight times more for the chair.

If I were writing a one-line buying rule from this two weeks of reporting, it would be: no chromatogram, no batch-specific endotoxin number, no needle.

Sources & further reading

1. FDA. List of Bulk Drug Substances for Use in Compounding under Section 503A — Category 2 (substances that raise significant safety risks). Updated 2020–2024.

2. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357:2359–2370. (PMID 18057338) — pivotal phase III tesamorelin trial.

3. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 2006;91:799–805. (PMID 16352683)

4. Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicentre, single-blind, randomised and controlled trial. Critical Care. 2013;17:R8. (PMID 23347688)

5. Sikirić P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Series of preclinical and limited human work, University of Zagreb group, 1990s–2020s. (Background literature on the BPC-157 mechanism case.)

6. FDA Drug Safety Communications and Compounding Quality Reports on compounded GLP-1 and peptide products, 2023–2024.

7. Longevity Latest Issue 09 — Peptides: Real Science or Rodent Studies with a Marketing Department? (Companion newsletter to this Deep Dive.)

© 2026 FrontWave Media Ltd | Longevity Latest

This article provides information for educational purposes only and is not medical advice. The Certificate of Analysis guidance above is a consumer-protection minimum, not an endorsement of unprescribed peptide use. Always consult a qualified healthcare professional before starting any new medication, supplement, or injection.

© 2026 FrontWave Media Ltd | longevitylatest.com